Nxera Pharma Co., Ltd.

DB:JSS Stock Report

Market Cap: €484.1m

Nxera Pharma Valuation

Is JSS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JSS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€0.89
Fair Value
484.7% overvalued intrinsic discount
10
Number of Analysts

Below Fair Value: JSS (€5.2) is trading above our estimate of fair value (€0.89)

Significantly Below Fair Value: JSS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JSS?

Key metric: As JSS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for JSS. This is calculated by dividing JSS's market cap by their current revenue.
What is JSS's PS Ratio?
PS Ratio2.6x
SalesJP¥28.84b
Market CapJP¥75.52b

Price to Sales Ratio vs Peers

How does JSS's PS Ratio compare to its peers?

The above table shows the PS ratio for JSS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.2x
PSG PharmaSGP Holding
2.7x7.3%€311.7m
DMP Dermapharm Holding
1.8x3.8%€2.1b
APPH Apontis Pharma
2.3x15.3%€94.1m
HIGH Cantourage Group
29.9x28.0%€58.6m
JSS Nxera Pharma
2.6x9.0%€75.5b

Price-To-Sales vs Peers: JSS is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (9.2x).

Price to Sales Ratio vs Industry

How does JSS's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

16 CompaniesPrice / SalesEstimated GrowthMarket Cap
JSS 2.6xIndustry Avg. 3.3xNo. of Companies22PS03.67.210.814.418+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: JSS is good value based on its Price-To-Sales Ratio (2.6x) compared to the European Pharmaceuticals industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is JSS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JSS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: JSS is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JSS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.20
€12.95
+149.1%
43.2%€28.15€6.88n/a10
Feb ’26€5.85
€12.86
+119.9%
41.8%€27.69€8.00n/a10
Jan ’26€6.25
€12.76
+104.1%
34.6%€24.39€8.13n/a10
Dec ’25€6.90
€12.64
+83.2%
33.5%€23.82€7.94n/a10
Nov ’25€7.15
€12.49
+74.6%
32.8%€23.53€7.84n/a10
Oct ’25€7.45
€13.13
+76.2%
30.7%€24.50€9.42n/a10
Sep ’25€8.55
€12.97
+51.8%
31.6%€23.84€9.17n/a9
Aug ’25€10.00
€12.42
+24.2%
31.6%€22.83€8.78n/a9
Jul ’25€8.85
€12.39
+40.0%
31.8%€22.89€8.81n/a9
Jun ’25€8.35
€12.39
+48.4%
31.8%€22.89€8.81n/a9
May ’25€8.55
€12.74
+49.0%
32.5%€23.66€9.10n/a9
Apr ’25€9.70
€12.91
+33.1%
34.2%€23.83€9.17n/a8
Mar ’25€9.35
€12.92
+38.2%
33.4%€23.85€9.17n/a8
Feb ’25€8.75
€13.48
+54.1%
32.2%€24.26€9.58€5.858
Jan ’25€8.90
€14.30
+60.7%
35.0%€26.79€9.82€6.258
Dec ’24€8.60
€14.00
+62.8%
37.3%€25.99€9.53€6.907
Nov ’24€8.55
€14.30
+67.2%
34.2%€26.32€9.71€7.158
Oct ’24€9.20
€14.74
+60.2%
35.1%€26.50€9.78€7.457
Sep ’24€10.30
€14.74
+43.1%
35.1%€26.50€9.78€8.557
Aug ’24€11.50
€16.12
+40.2%
35.7%€27.00€9.97€10.007
Jul ’24€15.30
€16.83
+10.0%
47.1%€28.51€6.97€8.857
Jun ’24€20.40
€23.21
+13.8%
24.3%€29.84€11.94€8.357
May ’24€17.60
€21.80
+23.9%
26.8%€28.48€12.21€8.557
Apr ’24€15.30
€21.93
+43.3%
28.8%€29.08€12.46€9.706
Mar ’24€14.50
€21.68
+49.5%
28.0%€29.06€12.45€9.356
Feb ’24€16.90
€21.53
+27.4%
28.1%€29.01€12.43€8.756
Analyst Price Target
Consensus Narrative from 10 Analysts
€12.81
Fair Value
59.4% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 06:10
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nxera Pharma Co., Ltd. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc
null nullCredit Suisse